TY - JOUR
T1 - A Japanese case of β-ureidopropionase deficiency with dysmorphic features
AU - Akiyama, Tomoyuki
AU - Shibata, Takashi
AU - Yoshinaga, Harumi
AU - Kuhara, Tomiko
AU - Nakajima, Yoko
AU - Kato, Takema
AU - Maeda, Yasuhiro
AU - Ohse, Morimasa
AU - Oka, Makio
AU - Kageyama, Misao
AU - Kobayashi, Katsuhiro
N1 - Publisher Copyright:
© 2016 The Japanese Society of Child Neurology
PY - 2017/1/1
Y1 - 2017/1/1
N2 - β-Ureidopropionase deficiency is a rare autosomal recessive disease affecting the last step of pyrimidine degradation, and it is caused by a mutation in the UPB1 gene. Approximately 30 cases have been reported to date, with a phenotypical variability ranging from asymptomatic to severe neurological illness. Non-neurological symptoms have been rarely reported. We describe a case of this disease with developmental delay and dysmorphic features. Gas chromatography–mass spectrometry-based urine metabolomics demonstrated significant (⩾+4.5 standard deviation after logarithmic transformation) elevations of β-ureidopropionic acid and β-ureidoisobutyric acid, strongly suggesting a diagnosis of β-ureidopropionase deficiency. Subsequent quantitative analysis of pyrimidines by liquid chromatography–tandem mass spectrometry supported this finding. Genetic testing of the UPB1 gene confirmed compound heterozygosity of a novel mutation (c.976C>T) and a previously-reported mutation (c.977G>A) that is common in East Asians. β-Ureidopropionase deficiency is probably underdiagnosed, considering a wide phenotypical variability, non-specific neurological presentations, and an estimated prevalence of 1/5000–6000. Urine metabolomics should be considered for patients with unexplained neurological symptoms.
AB - β-Ureidopropionase deficiency is a rare autosomal recessive disease affecting the last step of pyrimidine degradation, and it is caused by a mutation in the UPB1 gene. Approximately 30 cases have been reported to date, with a phenotypical variability ranging from asymptomatic to severe neurological illness. Non-neurological symptoms have been rarely reported. We describe a case of this disease with developmental delay and dysmorphic features. Gas chromatography–mass spectrometry-based urine metabolomics demonstrated significant (⩾+4.5 standard deviation after logarithmic transformation) elevations of β-ureidopropionic acid and β-ureidoisobutyric acid, strongly suggesting a diagnosis of β-ureidopropionase deficiency. Subsequent quantitative analysis of pyrimidines by liquid chromatography–tandem mass spectrometry supported this finding. Genetic testing of the UPB1 gene confirmed compound heterozygosity of a novel mutation (c.976C>T) and a previously-reported mutation (c.977G>A) that is common in East Asians. β-Ureidopropionase deficiency is probably underdiagnosed, considering a wide phenotypical variability, non-specific neurological presentations, and an estimated prevalence of 1/5000–6000. Urine metabolomics should be considered for patients with unexplained neurological symptoms.
UR - http://www.scopus.com/inward/record.url?scp=84996549622&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84996549622&partnerID=8YFLogxK
U2 - 10.1016/j.braindev.2016.08.001
DO - 10.1016/j.braindev.2016.08.001
M3 - Article
C2 - 27553092
AN - SCOPUS:84996549622
SN - 0387-7604
VL - 39
SP - 58
EP - 61
JO - Brain and Development
JF - Brain and Development
IS - 1
ER -